An early-stage life science development group currently backs more than 12 companies and the firm’s total investment across all technologies exceeds $100 million. The firm has a dual development strategy. The firm partners with academic inventors to found, manage, and develop companies to a point of exit or strategic partnering. When founding companies, the firm leverages non-dilutive grant funding where available alongside their investment group. The firm can also support early clinical-stage companies looking for financial and management support to perform clinical proof of concept studies; specifically a combination of investor funding and management support to round out the capabilities of the existing team. The firm and its affiliated investor groups have the ability to lead investment rounds of up to $20 million while also providing any required management support through its experienced team, including in preclinical, clinical and business development.

The firm invests across the biosciences space including Therapeutics, Diagnostics, and Medical Devices although the primary focus is on Therapeutics. The group is opportunistic in terms of subsectors and indications. Historically, the group has been active with companies developing novel therapeutics including drugs for defending against inhaled pathogenic threats, treatment of asthma, cancer, autoimmune diseases, and hearing loss, a biomedical assay platform technology, molecular diagnostics, antioxidant nanoparticles, robotic and imaging technologies, and cardiovascular devices.

The firm is interested in connecting with companies looking to generate clinical proof-of-concept data and that require funding as well as management support to complement the existing team. We are especially interested in companies that may have an interest in relocating to Houston.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Venture Capital firm based in the USA looks to make Series A equity investments ranging from $250,000 to $1.5 million in the initial round with up to $3 million reserved for follow on financing. Only on a case-by-case basis will the firm look to make seed investments. The firm focuses on companies in the United States and may also consider exceptional opportunities in Canada.

The firm is interested in investing in companies in the Medical Device, Diagnostics and to a much lesser extent Therapeutics spaces. The firm has a much stronger focus on devices with approximately 75% of the firm’s investments to date falling into those sectors. For Medical Devices the firm generally looks for companies that have either an early prototype or proof-of-concept data to support them. The firm is also currently interested in companies working with diagnostic devices and is not looking for companies in Orthopedics and Pain. For therapeutics companies the firm generally makes investment in pre-clinical assets and will evaluate opportunities on a case-by-case basis with priority given to less capital intensive opportunities.

The firm seeks privately held companies and maintains very positive and productive working relationships with its portfolio companies, providing as much assistance as needed.  The firm is much more open to taking significant scientific and technical risk as opposed to sales and marketing challenges.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital investment firm established in China with an additional office in the USA is investing from a fund with a focus on high-tech enterprises in China and western countries. The company seeks to invest in innovative enterprises in sectors including: biomedicine, medical devices, healthcare and bio-tech. Typical equity investments range from $1-6 million in Angel, Series A and B rounds. The firm is looking for opportunities in China, the US and Canada.

Within healthcare, the firm considers biomedicine, medical devices, and digital health. The firm is most interested in personalized medicine products with an angle to the China market. Within digital health, the firm prefers home-care, consumer, or physician-patient interface products. The firm considers products from Angel Round to Series B.

The firm is looking for competent management teams. The firm may request distribution rights on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm founded in 2018 invests in early-stage biotech and pharma companies. The firm invests in seed to Series A investment while it can also provide later funding (follow-up investment). The firm also seeks to In-licensing and NewCo spinout for later-stage research projects. The firm also has 30,000+ square feet of chemistry/biology incubator space in the USA. The firm also shares the same investment philosophy with its parent company, a global innovation incubator and investment group supported by Chinese partners.

The firm mainly looks at the biopharmaceutical industry. The firm prefers to work closely with scientific innovators to advance discoveries rapidly through key value-inflection points.

The firm does not have specific company requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A newly established venture capital firm headquartered in Western Europe leverages the experienced resources from a dedicated life sciences consulting firm (a separate entity), and is able to invest in and support in early-stage technologies with a derisked strategy. The firm has a pan-European focus and is sourcing globally within industry, start-up communities, and business accelerators, for high potential opportunities.

The firm is interested in proprietary, differentiated therapeutic products addressing high-unmet medical need and platform technologies supporting next-generation patient diagnosis, treatment and disease prevention. The interest areas also include genomics, AI, diagnostics, medical devices, rare diseases, next generation personalized medicine, and more. The firm is interested in early-stage opportunities – pre-clinical assets with a valid proof of concept, devices with a working prototype are all good fits in terms of stage of development.

The firm will look at each opportunity carefully, and is most interested in those with business potential with a 3-5 year runway to strategic partnerships, acquisition by large life science companies or an IPO. The firm will prefer to lead investments and will take a very active role in their portfolio companies, often being involved in the operations of these companies to support their growth and enabling research that generates important, proof-of-concept data.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based venture capital firm with a single LP looks to make growth-stage investments in the form of preferred equity, ranging from $1M-$5M initially, with additional capital reserved for follow-on financings, typically up to $10M over the life of the investment. The firm usually leads rounds, but is also open to syndicating with other investors. The firm looks to do 2-4 deals a year, and invests in U.S. and Canadian companies. Prospective companies may have some business overseas as long as they are headquartered in the U.S. or Canada.

The firm makes about one-half of its investments in healthcare, and is open to any healthcare companies that do not require FDA approval for their product/service. However, the firm focuses on B2B-oriented healthcare services and healthcare IT solutions. Some of the firm’s recent healthcare investments include a mobile telemedicine triage service company that provides mobile diabetic retinopathy eye exams as well as an EMR system to help orthopedic surgeons increase productivity.

The firm typically looks for growing companies with a run rate of at least $1M or a signed contract that would put them at a $1M run rate. The firm has no strict requirements in terms of management team, and will work with first-time entrepreneurs. The firm looks to take a board seat along with an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the USA has raised 3 funds to date and is currently investing out of its 3rd that closed at $20M. The firm makes primarily equity investments ranging from $250,000 to $5 million over the lifetime of the investment, with $100K-$500K as an initial investment. The firm has close relationships with several large Japanese medical technology corporations and also looks for ventures that they can introduce into the Japanese market. The firm prefers to invest in companies located in the West Coast if the US, although they are also open to review opportunities in North America.

The firm is looking for seed and venture-stage medical and diagnostic device companies. In these areas, the firm is most interested in single use therapeutic devices. The preferred regulatory pathway is a 510(k) submission, but PMA applications are also considered. Sectors with the most interest would be interventional  cardiovascular and neurovascular devices, less invasive surgical instrumentation, and point of care diagnostics. The firm remains open-minded to other types of devices and indications as well.

The firm looks for professionalism in a venture’s management team and is willing to work with firms that do not yet have a complete management team in place. The firm does not always look to take a board seat in portfolio companies, however they look to add value by developing corporate partnerships in Japan at the appropriate time.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.